Benzodioxoles: Novel Cannabinoid-1 Receptor Inverse Agonists for the Treatment of Obesity
Leo Alig(Roche (Switzerland)), Pius Waldmeier(Roche (Switzerland)), A. Mayweg(Roche (Switzerland)), Wolfgang Guba(Roche (Switzerland)), Anne Bourson(Roche (Switzerland)), Agnès Bénardeau(Roche (Switzerland)), Matthias Nettekoven(Roche (Switzerland)), Gisbert Schneider(ETH Zurich), Robert Narquizian(Roche (Switzerland)), Mark Rogers‐Evans(Roche (Switzerland)), Cynthia Rocha(Roche (Switzerland)), Stefan Hildbrand(Roche (Switzerland)), Stefanie Bendels(Roche (Switzerland)), Pascale David‐Pierson(Roche (Switzerland)), Jean‐Marc Plancher(Roche (Switzerland)), Stephan Röver(Roche (Switzerland)), Konrad Bleicher(Roche (Switzerland)), Werner Neidhart(Roche (Switzerland)), Sven Taylor(Roche (Switzerland)), Jochem Alsenz(Roche (Switzerland)), Dagmar Kube(Roche (Switzerland)), Thomas Lübbers(Roche (Switzerland)), Mirjana Andjelković(Roche (Switzerland))
Cited by 42
Related Papers
Designing antimicrobial peptides: form follows function
|Nature Reviews Drug Discovery|2011|2k
Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor
|Science|1995|1.8k
Fluorine in Medicinal Chemistry
|ChemBioChem|2004|1.5k
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
|Alzheimer s Research & Therapy|2017|568
Predicting drug metabolism: experiment and/or computation?
|Nature Reviews Drug Discovery|2015|500